1. Home
  2. NUVL vs RH Comparison

NUVL vs RH Comparison

Compare NUVL & RH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVL
  • RH
  • Stock Information
  • Founded
  • NUVL 2017
  • RH 1979
  • Country
  • NUVL United States
  • RH United States
  • Employees
  • NUVL N/A
  • RH N/A
  • Industry
  • NUVL Biotechnology: Pharmaceutical Preparations
  • RH Other Specialty Stores
  • Sector
  • NUVL Health Care
  • RH Consumer Discretionary
  • Exchange
  • NUVL Nasdaq
  • RH Nasdaq
  • Market Cap
  • NUVL 6.7B
  • RH 7.9B
  • IPO Year
  • NUVL 2021
  • RH 1998
  • Fundamental
  • Price
  • NUVL $87.30
  • RH $410.94
  • Analyst Decision
  • NUVL Strong Buy
  • RH Buy
  • Analyst Count
  • NUVL 10
  • RH 16
  • Target Price
  • NUVL $112.60
  • RH $398.87
  • AVG Volume (30 Days)
  • NUVL 350.8K
  • RH 808.4K
  • Earning Date
  • NUVL 11-12-2024
  • RH 12-12-2024
  • Dividend Yield
  • NUVL N/A
  • RH N/A
  • EPS Growth
  • NUVL N/A
  • RH N/A
  • EPS
  • NUVL N/A
  • RH 3.51
  • Revenue
  • NUVL N/A
  • RH $3,106,607,000.00
  • Revenue This Year
  • NUVL N/A
  • RH $7.46
  • Revenue Next Year
  • NUVL N/A
  • RH $11.09
  • P/E Ratio
  • NUVL N/A
  • RH $117.34
  • Revenue Growth
  • NUVL N/A
  • RH 1.41
  • 52 Week Low
  • NUVL $61.80
  • RH $212.43
  • 52 Week High
  • NUVL $113.51
  • RH $457.26
  • Technical
  • Relative Strength Index (RSI)
  • NUVL 36.14
  • RH 60.35
  • Support Level
  • NUVL $84.64
  • RH $406.40
  • Resistance Level
  • NUVL $89.31
  • RH $457.26
  • Average True Range (ATR)
  • NUVL 2.82
  • RH 14.92
  • MACD
  • NUVL -0.72
  • RH 2.13
  • Stochastic Oscillator
  • NUVL 20.93
  • RH 47.24

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About RH RH

RH is a luxury furniture and lifestyle retailer operating in the $134 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories including furniture, lighting, textiles, bath, decor, and children and is growing the presence of its hospitality business with 18 restaurant locations. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade by expanding abroad, with its World of RH digital platform (highlighting offerings outside of home furnishings), and with offerings in color, bespoke furniture, architecture, media, and more.

Share on Social Networks: